Opportunities for structure-based design of protease-directed drugs.

As a result of the recent enormous technological progress, experimental structure determination has become an integral part of the development of drugs against disease-related target proteins. The post-translational modification of proteins is an important regulatory process in living organisms; one such example is lytic processing by peptidases. Many different peptidases represent disease targets and are being used in structure-based drug design approaches. The development of drugs such as aliskiren and tipranavir, which inhibit renin and HIV protease, respectively, testifies to the success of this approach.

[1]  Hajime Niwa,et al.  Structure of the whole cytosolic region of ATP-dependent protease FtsH. , 2006, Molecular cell.

[2]  R. Stevens,et al.  Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. , 2006, Biochemistry.

[3]  Zheng Yin,et al.  Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus , 2006, Nature Structural &Molecular Biology.

[4]  F. Avilés,et al.  Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Stephen Hanessian,et al.  Structure-based design and synthesis of macroheterocyclic peptidomimetic inhibitors of the aspartic protease beta-site amyloid precursor protein cleaving enzyme (BACE). , 2006, Journal of medicinal chemistry.

[6]  R. Natesh,et al.  Structure of angiotensin I-converting enzyme. , 2004, Cellular and molecular life sciences : CMLS.

[7]  F. Avilés,et al.  Detailed molecular comparison between the inhibition mode of A/B-type carboxypeptidases in the zymogen state and by the endogenous inhibitor latexin , 2005, Cellular and Molecular Life Sciences CMLS.

[8]  Jukka Kervinen,et al.  Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[9]  Francesco Leonetti,et al.  Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.

[10]  J. Vederas,et al.  Dual Modes of Modification of Hepatitis A Virus 3C Protease by a Serine-derived β-Lactone: Selective Crystallization and Formation of a Functional Catalytic Triad in the Active Site , 2005, Journal of Molecular Biology.

[11]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[12]  D. Hume,et al.  An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. , 2005, Structure.

[13]  Yigong Shi,et al.  Structure and Activation Mechanism of the Drosophila Initiator Caspase Dronc* , 2006, Journal of Biological Chemistry.

[14]  Robert Huber,et al.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[16]  M Katharine Holloway,et al.  Conformationally biased P3 amide replacements of beta-secretase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[17]  Jun Liu,et al.  Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Adler,et al.  Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B. , 2005, Biochemistry.

[19]  Hao Wu,et al.  Native chemical ligation in covalent caspase inhibition by p35. , 2006, Chemistry & biology.

[20]  Markus Meister,et al.  The molecular architecture of the metalloprotease FtsH. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. G. Njoroge,et al.  Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid. , 2006, Bioorganic & medicinal chemistry letters.

[22]  Steven R. LaPlante,et al.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.

[23]  S. Swaminathan,et al.  Structural analysis of the catalytic domain of tetanus neurotoxin. , 2005, Toxicon : official journal of the International Society on Toxinology.

[24]  G. Scapin,et al.  (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2006, Journal of medicinal chemistry.

[25]  Mindy I. Davis,et al.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Paul J Edwards,et al.  The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[27]  Dawoon Jung,et al.  Efficient synthetic inhibitors of anthrax lethal factor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Rosenthal,et al.  The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Ploegh,et al.  Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. , 2006, Structure.

[30]  Wenfang Xu,et al.  Progress in the development of aminopeptidase N (APN/CD13) inhibitors. , 2005, Current medicinal chemistry. Anti-cancer agents.

[31]  J. Konvalinka,et al.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer , 2006, The EMBO journal.

[32]  Axel T. Brunger,et al.  Substrate recognition strategy for botulinum neurotoxin serotype A , 2004, Nature.

[33]  V. Madison,et al.  Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease. , 2005, Bioorganic & medicinal chemistry letters.

[34]  E. Scolnick,et al.  Anthrax lethal factor inhibition , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Stephen Hanessian,et al.  Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. , 2005 .

[36]  M. Sakata,et al.  Unusual Extra Space at the Active Site and High Activity for Acetylated Hydroxyproline of Prolyl Aminopeptidase from Serratia marcescens , 2006, Journal of bacteriology.

[37]  L. Prade,et al.  X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor* , 2005, Journal of Biological Chemistry.

[38]  I. Mathews,et al.  Structural and mechanistic analysis of two prolyl endopeptidases: role of interdomain dynamics in catalysis and specificity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Fletterick,et al.  Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[41]  Markus G Grütter,et al.  Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis. , 2006, Journal of molecular biology.

[42]  Walter Huber,et al.  Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. , 2003, Structure.

[43]  J. Wells,et al.  A common allosteric site and mechanism in caspases , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Jian Sun,et al.  Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. , 2006, Journal of medicinal chemistry.

[45]  A. Pessi,et al.  Inhibiting viral proteases: challenges and opportunities. , 2002, Biopolymers.

[46]  S. Swaminathan,et al.  Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. , 2005, Biochemistry.

[47]  S. Srinivasula,et al.  Engineering a Dimeric Caspase-9: A Re-evaluation of the Induced Proximity Model for Caspase Activation , 2005, PLoS biology.

[48]  V. Madison,et al.  Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency. , 2005, Bioorganic & medicinal chemistry letters.

[49]  Xu Shen,et al.  Structural and Functional Characterization of Falcipain-2, a Hemoglobinase from the Malarial Parasite Plasmodium falciparum* , 2006, Journal of Biological Chemistry.